Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr -/- mice

Annals of the Rheumatic Diseases

Volumn 71, Issue 3, 2012, Pages 408-414

  Van Leuven, Sander I ^a,b   Mendez Fernandez, Yanice V ^a   Wilhelm, Ashley J ^a   Wade, Nekeithia S ^a   Gabriel, Curtis L ^a   Kastelein, John J ^b   Stroes, Erik S ^b   Tak, Paul P ^b   Major, Amy S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; DOUBLE STRANDED DNA ANTIBODY; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; KIDNEY FUNCTION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN DEFICIENCY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ANIMALS; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MYCOPHENOLIC ACID; PYRROLES;

EID: 84857232987     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200071     Document Type: Article

References (31)

1. Perl A. Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity 2010;43:1-6.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
3. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 2007;19:633-9. (Pubitemid 350236815)
4. van Leuven SI, Franssen R, Kastelein JJ, et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008;47:3-7. (Pubitemid 350286254)
5. Sherer Y, Zinger H, Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity 2010;43:98-102.
6. Sarzi-Puttini P, Atzeni F, Gerli R, et al. Cardiac involvement in systemic rheumatic diseases: An update. Autoimmun Rev 2010;9:849-52.
7. Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70:760-5.
8. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118. (Pubitemid 30394534)
9. Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci 2007;1110:209-21. (Pubitemid 350043010)
10. van Leuven SI, van Wijk DF, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 2010;211:231-6.
11. Stanic AK, Stein CM, Morgan AC, et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci USA 2006;103:7018-23.
12. Morel L, Rudofsky UH, Longmate JA, et al. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994;1:219-29.
13. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989;143:103-12. (Pubitemid 19174206)
14. Chong WP, Ip WK, Wong WH, et al. Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus. Genes Immun 2004;5:484-92. (Pubitemid 39263884)
15. Eskdale J, Wordsworth P, Bowman S, et al. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997;49:635-9. (Pubitemid 27267885)
16. Lin YJ, Wan L, Huang CM, et al. IL-10 and TNF-alpha promoter polymorphisms in susceptibility to systemic lupus erythematosus in Taiwan. Clin Exp Rheumatol 2010;28:318-24.
17. Rosado S, Rua-Figueroa I, Vargas JA, et al. Interleukin-10 promoter polymorphisms in patients with systemic lupus erythematosus from the Canary Islands. Int J Immunogenet 2008;35:235-42. (Pubitemid 351678690)
18. Sobkowiak A, Lianeri M, Wudarski M, et al. Genetic variation in the interleukin-10 gene promoter in Polish patients with systemic lupus erythematosus. Rheumatol Int 2009;29:921-5.
19. Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007;27:461-6.
20. Hagiwara E, Gourley MF, Lee S, et al. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-85. (Pubitemid 26085213)
21. Park YB, Lee SK, Kim DS, et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8. (Pubitemid 28219167)
22. Ishida H, Muchamuel T, Sakaguchi S, et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10. (Pubitemid 24012996)
23. Kalechman Y, Gafter U, Da JP, et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J Immunol 1997;159:2658-67. (Pubitemid 127681284)
24. Blenman KR, Duan B, Xu Z, et al. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest 2006;86:1136-48. (Pubitemid 44624150)
25. Caligiuri G, Rudling M, Ollivier V, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003;9:10-17. (Pubitemid 36667687)
26. Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002;90:1064-71. (Pubitemid 34627904)
27. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847-53. (Pubitemid 30029809)
28. Potteaux S, Esposito B, van Oostrom O, et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2004;24:1474-8. (Pubitemid 39050443)
29. Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010;207:1579-87.
30. Kyaw T, Tay C, Khan A, et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010;185:4410-19.
31. Anania C, Gustafsson T, Hua X, et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010;12:R214.